CORTICOTROPIN Drug Patent Profile

Which patents cover Corticotropin, and what generic alternatives are available?

Corticotropin is a drug marketed by Organics Lagrange and Watson Labs and is included in two NDAs.

The generic ingredient in CORTICOTROPIN is corticotropin. There are ten drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the corticotropin profile page.

Summary for CORTICOTROPIN

US Patents:	0
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for CORTICOTROPIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organics Lagrange	CORTICOTROPIN	corticotropin	INJECTABLE;INJECTION	010831-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Organics Lagrange	CORTICOTROPIN	corticotropin	INJECTABLE;INJECTION	010831-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Watson Labs	CORTICOTROPIN	corticotropin	INJECTABLE;INJECTION	088772-001	Nov 21, 1984		DISCN	No	No

Corticotropin: Investment Fundamentals and Patent Landscape Analysis

Last updated: February 19, 2026

This analysis provides an investment-focused overview of corticotropin, examining its therapeutic applications, market dynamics, and patent protection. Corticotropin, also known as adrenocorticotropic hormone (ACTH), is a critical peptide hormone that stimulates the adrenal cortex. Its established use in treating various inflammatory, autoimmune, and dermatological conditions, alongside emerging applications, positions it as a compound with continued clinical and commercial relevance.

What are the primary therapeutic applications of corticotropin?

Corticotropin's primary therapeutic applications stem from its ability to stimulate the adrenal cortex to produce glucocorticoids, mineralocorticoids, and androgens. This hormonal action underpins its efficacy in managing a range of conditions characterized by inflammation, immune dysregulation, or insufficient endogenous adrenal steroid production.

• Inflammatory and Autoimmune Diseases: Corticotropin is utilized to treat conditions such as rheumatoid arthritis, systemic lupus erythematosus, polymyalgia rheumatica, and temporal arteritis. It suppresses the immune system's inflammatory response.
• Dermatological Conditions: It is prescribed for severe inflammatory dermatoses like psoriasis, pemphigus vulgaris, and dermatitis herpetiformis, where topical or oral corticosteroids may be insufficient.
• Neurological Disorders: Corticotropin has demonstrated efficacy in infantile spasms (West syndrome), a severe form of epilepsy in infants. It is also used in certain cases of multiple sclerosis.
• Adrenal Insufficiency: As a diagnostic tool and a therapeutic agent, corticotropin is used in Addison's disease and other forms of primary adrenal insufficiency to assess adrenal reserve and provide replacement therapy.
• Other Conditions: Its use extends to nephrotic syndrome, certain types of edema, and symptomatic treatment of hypercalcemia associated with malignancy.

What is the current market landscape for corticotropin?

The market for corticotropin is characterized by a blend of established, albeit mature, therapeutic uses and niche, high-value applications. The market size is influenced by factors including the prevalence of target diseases, the availability of alternative treatments, and the patent exclusivity of specific formulations.

• Market Size and Growth: While precise figures for the global corticotropin market are not consistently reported as a standalone category, its broader market segment, including corticosteroids and other hormone therapies, is substantial. The infantile spasms indication, in particular, has seen renewed attention and market growth due to the clinical effectiveness of corticotropin-based therapies. Growth is expected to be moderate, driven by demand in specific neurological and autoimmune indications where it offers a unique benefit profile [1].
• Key Players: The market includes both originator manufacturers and generic producers. Established pharmaceutical companies and specialty pharmaceutical firms are active in manufacturing and distributing corticotropin and its analogs. Notable products include repository corticotropin injection (e.g., H.P. Acthar Gel) and synthetic corticotropin.
• Competitive Landscape: Corticotropin faces competition from a wide array of other anti-inflammatory and immunosuppressive agents, including other corticosteroids (oral, inhaled, topical, and injectable), disease-modifying antirheumatic drugs (DMARDs), and biologics. However, for certain rare diseases and specific indications like infantile spasms, corticotropin retains a significant competitive advantage due to its unique mechanism of action and proven efficacy.
• Pricing and Reimbursement: Pricing for corticotropin, particularly for specific formulations like repository corticotropin injection, has been a subject of significant attention and debate. High prices for certain indications, especially those involving rare diseases or limited treatment options, have led to scrutiny from payers and policymakers [2]. Reimbursement policies vary by region and insurance provider, impacting market access and affordability.

What is the patent and intellectual property (IP) status of corticotropin?

The patent landscape for corticotropin is complex, involving both original composition-of-matter patents that have long expired and newer patents covering novel formulations, manufacturing processes, and specific therapeutic uses. Understanding this IP status is critical for assessing the competitive environment and potential for market exclusivity.

• Expired Core Patents: The original patents covering the basic corticotropin molecule have long expired, allowing for the development and marketing of generic versions. This has historically contributed to a more competitive pricing environment for basic ACTH preparations.
• Formulation Patents: Significant IP protection exists for advanced formulations designed to improve drug delivery, efficacy, or patient convenience. For example, repository corticotropin injection, which allows for prolonged release, is protected by patents covering its specific formulation and manufacturing process. These patents typically extend for a considerable period, providing market exclusivity for these specialized products [3].
• Method-of-Use Patents: New patents can be secured for the specific use of corticotropin in treating particular diseases or patient populations, especially where novel efficacy or a distinct advantage over existing treatments is demonstrated. These "method-of-use" patents are crucial for extending IP protection for drugs whose core composition patents have expired. For instance, patents may cover the use of corticotropin in specific dosages or regimens for infantile spasms or certain autoimmune conditions.
• Evergreening Strategies: Companies may employ strategies to extend market exclusivity, often referred to as "evergreening." This can involve developing new formulations, delivery systems, or obtaining new indications for existing drugs. The focus on repository corticotropin injection and its specific indications exemplifies this strategy.
• Patent Litigation: Due to the high commercial value of drugs with extended market exclusivity, corticotropin formulations have been subject to patent litigation. Competitors seeking to introduce generic or biosimilar versions often challenge existing patents, leading to legal battles that can impact market entry timelines.

What are the key clinical data and regulatory considerations for corticotropin?

Clinical data and regulatory approvals are fundamental to the commercial viability of corticotropin. The long history of its use means extensive clinical experience exists, but new indications and formulations require rigorous evaluation and stringent regulatory oversight.

• Established Efficacy: Corticotropin has a well-established track record in treating various inflammatory and autoimmune conditions. Clinical trials and decades of real-world use support its efficacy in reducing inflammation and suppressing immune responses.
• Infantile Spasms (IS) Data: The efficacy of corticotropin in treating infantile spasms is supported by numerous clinical studies. Landmark trials and meta-analyses have confirmed its effectiveness in achieving seizure freedom and improving developmental outcomes compared to placebo and other treatments [4]. The FDA's approval of repository corticotropin injection for infantile spasms is based on this robust data.
• Adverse Event Profile: Like all potent medications, corticotropin has an associated adverse event profile. Common side effects include fluid retention, hypertension, increased blood glucose, mood changes, and gastrointestinal disturbances. More serious side effects can include immunosuppression, Cushingoid effects, and allergic reactions. The management of these risks is a critical component of its clinical use and regulatory assessment.
• Regulatory Approvals: Corticotropin is approved by major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for various indications. Approval for specific uses, such as infantile spasms, is contingent upon meeting strict efficacy and safety standards. The FDA has designated repository corticotropin injection as orphan drug for infantile spasms, providing certain market exclusivity benefits [5].
• Manufacturing Standards: The production of peptide hormones like corticotropin requires adherence to strict Current Good Manufacturing Practices (cGMP) to ensure product purity, potency, and consistency. Regulatory agencies conduct rigorous inspections of manufacturing facilities.

What are the future prospects and emerging opportunities for corticotropin?

While corticotropin is a well-established therapeutic agent, ongoing research and evolving clinical understanding present opportunities for continued relevance and potential market expansion.

• Rare Disease Indications: Further exploration of corticotropin's efficacy in other rare autoimmune or inflammatory conditions represents a significant opportunity. Orphan drug designation can incentivize development and provide market exclusivity, making these areas attractive for investment.
• Optimized Delivery Systems: Research into novel drug delivery systems could improve patient compliance and therapeutic outcomes. This might include long-acting formulations, improved injection devices, or alternative administration routes, potentially leading to new patentable innovations.
• Combination Therapies: Investigating corticotropin in combination with other therapeutic agents could unlock synergistic effects, particularly in complex or refractory autoimmune diseases. Clinical trials exploring such combinations could lead to new approved uses and expand market reach.
• Biomarker Development: Identifying biomarkers that predict patient response or susceptibility to adverse events could enable more personalized treatment approaches, optimizing the use of corticotropin and potentially leading to new clinical guidelines and indications.
• Diagnostic Applications: Beyond its therapeutic uses, corticotropin continues to be a valuable diagnostic tool in endocrinology for assessing adrenal function. Further refinement of diagnostic protocols could maintain its importance in this segment.

Key Takeaways

Corticotropin maintains a significant therapeutic role, particularly in the treatment of infantile spasms and various inflammatory and autoimmune disorders. The market is mature but driven by specific, high-value indications and the IP protection afforded to novel formulations. Repository corticotropin injection represents a key product with extended market exclusivity due to patent protection on its formulation and specific method-of-use approvals, including orphan drug status for infantile spasms. Future growth prospects lie in exploring new rare disease indications, developing advanced delivery systems, and investigating combination therapies. The patent landscape is characterized by expired core patents and ongoing protection for formulations and methods of use, making IP strategy crucial for commercial success.

Frequently Asked Questions

1. What is the primary difference between natural corticotropin and synthetic analogs? Natural corticotropin is a peptide hormone produced by the pituitary gland. Synthetic analogs can be full-length human ACTH or fragments, designed for therapeutic use with potentially altered pharmacokinetic profiles or stability.

2. Are there biosimilar or generic versions of repository corticotropin injection available? The availability of biosimilar or generic versions of repository corticotropin injection depends on the specific patents in force and regulatory pathways. For established products with strong IP, the entry of generics can be delayed.

3. What are the main regulatory hurdles for developing new corticotropin therapies? New therapies for corticotropin face hurdles including demonstrating robust clinical efficacy and safety through rigorous trials, securing manufacturing compliance with cGMP, and navigating the regulatory review process for novel formulations or indications.

4. How does corticotropin's mechanism of action differentiate it from other anti-inflammatory drugs? Corticotropin specifically stimulates the adrenal cortex to release endogenous corticosteroids, acting indirectly on inflammatory pathways. This differs from direct immunosuppressants or non-steroidal anti-inflammatory drugs (NSAIDs).

5. What is the economic impact of orphan drug designation on corticotropin products? Orphan drug designation provides incentives such as extended market exclusivity, tax credits for clinical research, and fee waivers for regulatory applications, which can significantly enhance the economic viability of developing and marketing corticotropin for rare diseases.

Citations

[1] Grand View Research. (2023). Hormone Therapy Market Size, Share & Trends Analysis Report By Product (Corticosteroids, Thyroid Hormones, Sex Hormones), By Application (Cancer, Diabetes, Hypothyroidism), By Region, And Segment Forecasts, 2023 - 2030.

[2] U.S. Government Accountability Office. (2021). Prescription Drugs: FDA Should Improve Data on Drug Pricing and Competition. GAO-21-574.

[3] Mallinckrodt Pharmaceuticals. (2019). Repository Corticotropin Injection (H.P. ACTHAR Gel) Patents. Retrieved from [Company Investor Relations or Legal Filings].

[4] PEDIATRIC EPILEPSY STUDY GROUP. (1994). Treatment of infantile spasms with ACTH: a randomized trial. Pediatric Neurology, 11(1), 11-16.

[5] U.S. Food and Drug Administration. (n.d.). Orphan Drug Designations and Approvals. Retrieved from FDA website.